Development of a selective and potent radioactive ligand for histamine H3 receptors: A compound potentially useful for receptor occupancy studies
摘要:
Radioligands are powerful tools for examining the pharmacological profiles of chemical leads and thus facilitate drug discovery. In this study, we identified and characterized 3-([1,1,1-H-3]methyl)-2-(4-{[3-(1-pyrrolidinyl)propyl]oxy} phenyl)-4(3H)-quinazolinone ([H-3]1) as a potent and selective radioligand for histamine H-3 receptors. Radioligand [H-3]1 exhibited appreciable specific signal in brain slices prepared from wild-type mice but not from histamine H-3 receptor-deficient mice, demonstrating the specificity and utility of [H-3]1 as a selective histamine H-3 receptor radioligand for ex-vivo receptor occupancy assays. (C) 2009 Elsevier Ltd. All rights reserved.
Development of a selective and potent radioactive ligand for histamine H3 receptors: A compound potentially useful for receptor occupancy studies
摘要:
Radioligands are powerful tools for examining the pharmacological profiles of chemical leads and thus facilitate drug discovery. In this study, we identified and characterized 3-([1,1,1-H-3]methyl)-2-(4-{[3-(1-pyrrolidinyl)propyl]oxy} phenyl)-4(3H)-quinazolinone ([H-3]1) as a potent and selective radioligand for histamine H-3 receptors. Radioligand [H-3]1 exhibited appreciable specific signal in brain slices prepared from wild-type mice but not from histamine H-3 receptor-deficient mice, demonstrating the specificity and utility of [H-3]1 as a selective histamine H-3 receptor radioligand for ex-vivo receptor occupancy assays. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] OXYNTOMODULIN ANALOGS<br/>[FR] ANALOGUES DE L'OXYNTOMODULINE
申请人:MERCK SHARP & DOHME
公开号:WO2010096142A1
公开(公告)日:2010-08-26
Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist, are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.